How can we prevent multisystem complications of cystic fibrosis?

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 3, 2007, Pages 303-311

  Elborn, J Stuart ^a,b,c  

^a Respiratory Medicine Group   (Ireland)

^b BCH   (Ireland)

^c BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; Diabetes; Inflammation; Liver disease; Osteoporosis

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTHROPATHY; BONE DISEASE; CYSTIC FIBROSIS; DIABETES MELLITUS; HUMAN; INFLAMMATORY DISEASE; MORTALITY; PRIORITY JOURNAL; REVIEW; SYSTEMIC DISEASE; VASCULITIS;

ARTHRITIS; AVITAMINOSIS; CELLULITIS; CYSTIC FIBROSIS; DIABETES MELLITUS; HUMANS; INFLAMMATION; LIVER DISEASES; MALNUTRITION; OSTEOPOROSIS;

EID: 34250824138     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981651     Document Type: Review

References (86)

1. Chimiel JF, Konston MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007;28: 331-346
2. Gibson RL, Burns J, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951
3. UK Cystic Fibrosis Trust Nutrition Working Group. Nutritional Management of Cystic Fibrosis. Bromley, Kent: Cystic Fibrosis Trust; 2002
4. Lindley KJ. Pancreatic involvement: clinical manifestations, pathophysiology and new treatments. In: A Bush, EWFW Alton, JC Davies, U Griesenbach, A Jaffe, eds. Cystic Fibrosis in the 21st Century. Progressive Respiratory Research, vol. 34. Basel: Karger; 2006:242-250
5. Ahmed N, Corey M, Forstner G, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 2003;52:1159-1164
6. Westaby D. Cystic fibrosis: liver disease. In: A Bush, EWFW Alton, JC Davies, U Griesenbach, A Jaffe, eds. Cystic Fibrosis in the 21st Century. Progressive Respiratory Research, vol 34. Basel: Karger; 2006:251-261
7. Knowles MR, Durie PR. What is cystic fibrosis? N Engl J Med 2002;347:439-442
8. Murphy JL, Wootton SA, Bond SA, Jackson AA. Energy content of stools in healthy controls and patients with cystic fibrosis. Arch Dis Child 1991;66:495-500
9. Bell SC, Shepherd RW. Optimising nutrition in cystic fibrosis. J Cyst Fibros 2002;1:47-50
10. Abbott J, Conway SP, Etherington C, et al. Perceived body image and eating behaviour in young adults with cystic fibrosis and their healthy peers. J Behav Med 2000;23:501-517
11. Duff AJA, Wolfe SP, Dickson C, Conway SP, Brownlee KG. Feeding behaviour problems in children with cystic fibrosis in the UK: prevalence and comparison with healthy controls. J Pediatr Gastroenterol Nutr 2003;36:443-447
12. Poustie VJ, Russell JE, Watling RM, Ashby D, Smyth RL, CALICO Trial Collaborative Group. Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial. BMJ 2006; 332:632-636
13. Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis. Thorax 1996;51:126-131
14. Bradley J, McAllister O, Elborn JS. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Respir J 2001;17:712-715
15. Bell SC, Bowerman AM, Nixon LE, MacDonald IA, Elborn JS, Shale DJ. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest 2000;30:553-559
16. McCloskey M, Redmond AOB, Pyper S, McCabe C, Westerterp KP, Elborn JS. Total energy expenditure in stable patients with cystic fibrosis. Clin Nutr 2001;20:235-241
17. Courtney JM, Ennis M, Elborn JS. Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros 2004;3:223-231
18. Fried MD, Durie PR, Tsui LC, Corey M, Levison H, Pencharz PB. The cystic fibrosis gene and resting energy expenditure. J Pediatr 1991;119:913-916
19. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-642
20. Saiman L, Marshall BC, Mayer-Hamblett N, et al; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756
21. Hardin DS, Rice J, Ahn C, et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. J Pediatr 2005;146:324-328
22. Boguszewski MC, Kamoi TO, Bento Radominski R, et al. Insulin-like growth factor-1, leptin, body composition, and clinical status interactions in children with cystic fibrosis. Horm Res 2007;67:250-256
23. Eubanks V, Koppersmith N, Wooldridge N, et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. J Pediatr 2002;140:439-444
24. Elkin SL, Verdi S, Bord S, Garrahan NJ, Hodson ME, Compston JE. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am J Respir Crit Care Med 2002;166:1470-1474
25. Haworth CS, Selby PL, Webb AK, et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999;54:961-967
26. Rossini M, Del Marco A, Dal Santo F, et al. Prevalence and correlates of vertebral fractures in adults with cystic fibrosis. Bone 2004;35:771-776
27. Bone disease in cystic fibrosis. Cystic Fibrosis Trust 2007. www.cftrust.org.uk
28. Conway SP, Morton AM, Oldroyd B, et al. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax 2000;55:798-804
29. Haworth CS, Selby PL, Webb AK, et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999;54:961-967
30. Aris RM, Merkel PA, Bachrach LK, et al. Consensus statement: guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005;90:1888-1896
31. Hardin DS, Arumugam R, Seillheimer DK, LeBlanc A, Ellis KJ. Normal bone mineral density in cystic fibrosis. Arch Dis Child 2001;84:363-368
32. Ionescu AA, Nixon LS, Evans WD, et al. Bone density, body composition and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med 2000;162:789-794
33. Aris RM, Ontjes DA, Brown SA, Chalermskulrat W, Neuringer I, Lester GE. Carboxylated osteocalcin levels in cystic fibrosis [letter]. Am J Respir Crit Care Med 2003;168: 1129
34. King SJ, Topliss DJ, Kotsimbos T, et al. Reduced bone density in cystic fibrosis: ΔF508 mutation is an independent risk factor. Eur Respir J 2005;25:54-61
35. Dif F, Marty C, Baudoin C, de Vernejoul MC, Levi G. Severe osteopenia in CFTR-null mice. Bone 2004;35:595-603
36. Buntain HM, Greer RM, Schluter PJ, et al. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax 2004;59:149-155
37. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005;90:1888-1896
38. Aris RM, Stephens AR, Ontjes DA, et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am J Respir Crit Care Med 2000;162:1674-1678
39. Haworth CS, Selby PL, Webb AK, et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004;59:613-617
40. Boyle MP, Lechtzin N, Merlo CA, et al. Determination of ideal serum 25-hydroxyvitamin D levels in adults with CF by evaluation of effects on parathyroid hormone levels [abstract]. Pediatr Pulmonol 2005;28:353
41. Bonjour JP, Chevalley T, Amman P, Slosman D, Rizzofi R. Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study. Lancet 2001;358:1208-1212
42. Conway SP, Wolfe SP, Brownless KG, et al. Vitamin K status in children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics 2005;115:1325-1331
43. McKay HA, Petit MA, Schutz RW, Prior JC, Barr SI, Khan KM. Augmented trochanteric bone mineral density after modified physical education classes: a randomised, school-based exercise intervention study in prepubescent and early pubescent children. J Pediatr 2000;136:156-162
44. Aris RM, Lester GE, Caminiti M, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004;169:77-82
45. Conway SP, Oldroyd B, Morton A, Truscott JG, Peckham DG. Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax 2004;59:699-703
46. Haworth CS, Selby PL, Adams JE, Mawer EB, Horrocks AM, Webb AK. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001;56: 314-316
47. Elkin S. Arthritis, vasculitis and bone disease. In: A Bush, EWFW Alton, JC Davies, U Griesenbach, A Jaffe, eds. Cystic Fibrosis in the 21st Century. Progressive Respiratory Research, vol 34. Basel: Karger; 2006:270-277
48. Finnegan MJ, Hinchcliffe J, Russell-Jones D, et al. Vasculitis complicating cystic fibrosis. QJ Med 1989;72:609-621
49. Zhao MH, Jayne DR, Ardiles LG, Culley F, Hodson ME, Lockwood CM. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM 1996;89:259-265
50. Management of cystic fibrosis diabetes mellitus. Cystic Fibrosis Trust 2004. www.cftrust.org.uk
51. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Geneva: WHO; 2006
52. Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros 2004;3:209-222
53. Stalvey MS, Muller C, Schatz DA, et al. Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury. Diabetes 2006;55: 1939-1945
54. Bridges N, Spowart K. Diabetes in cystic fibrosis. In: A Bush, EWFW Alton, JC Davies, U Griesenbach, A Jaffe, eds. Cystic Fibrosis in the 21st Century. Progressive Respiratory Research, vol 34. Basel: Karger; 2006:278-283
55. Hardin DS, Leblanc A, Marshall G, Seilheimer DK. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab 2001;281:E1022-E1028
56. Mueller-Brandes C, Holl RW, Nastoll M, Ballmann M. New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis. Eur Respir J 2005;25:715-717
57. Koch C, Rainisio M, Madessani U, et al; Investigators of the European Epidemiologic Registry of Cystic Fibrosis. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001;32:343-350
58. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162:891-895
59. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005;28:2141-2144
60. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 2004;21:691-696
61. Corbett K, Kellecher S, Rowland M, et al. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr 2004;145:327-332
62. Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004;41:920-925
63. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992;15:677-684
64. Sokol RJ, Durie PR. Recommendations for management of liver biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999;28:S1-S13
65. Colombo C, Crosignani A, Assaisso M, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992;16:924-930
66. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998;27:166-174
67. Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis related liver disease. Cochrane Database Syst Rev 2000;(2):CD00222
68. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a controlled trial. Hepatology 1992;16:707-714
69. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut 2000;46:S3-S4:III1-III15
70. Pozler O, Krajina A, Vanicek H, et al. Transjugular intrahepatic portosystemic shunt in five children with cystic fibrosis: long-term results. Hepatogastroenterology 2003;50: 1111-1114
71. De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics 2005;115:e463-e469 Epub 2005 Mar 16
72. Gilljam M, Ellis L, Corey M, Zielenski J, Durie P, Tullis DE. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest 2004;126:1215-1224
73. Durno C, Corey M, Zielenski J, Tullis E, Tsui LC, Durie P. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 2002;123:1857-1864
74. Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet 2005;118:372-381 Epub 2005 Sep 29
75. Nutritional management of cystic fibrosis. Cystic Fibrosis Trust. www.cftrust.org.uk
76. Campbell DC, Tole DM, Doran RML, Conway SP. Vitamin A deficiency in cystic fibrosis resulting in severe xerophthalmia. J Hum Nutr Diet 1998;11:529-532
77. Back EI, Frindt C, Nohr D, et al. Antioxidant deficiency in cystic fibrosis: when is the right time to take action? Am J Clin Nutr 2004;80:374-384
78. Oudshoorn JH, Klijn PH, Hofman Z, et al. Dietary supplementation with multiple micronutrients: No beneficial effects in pediatric cystic fibrosis patients. J Cyst Fibros 2007;6:35-40 Epub 2006 Jun 19
79. Greer RM, Buntain HM, Lewindon PJ, et al. Vitamin A levels in patients with CF are influenced by the inflammatory response. J Cyst Fibros 2004;3:143-149
80. Boyle MP, Noschese ML, Watts SL, Davis ME, Stenner SE, Lechtzin N. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med 2005;172:212-217
81. Wilson DC, Rashid M, Durie PR, et al. Treatment of vitamin K deficiency in cystic fibrosis: effectiveness of a daily fat-soluble vitamin combination. J Pediatr 2001;138:851-855
82. Nicolaidou P, Stavrinadis I, Loukou I, et al. The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. Eur J Pediatr 2006;165:540-545
83. Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN. Anti-TNF therapy: where have we got to in 2005? J Autoimmun 2005;25:26-28 Epub 2005 Nov 2
84. Antoniu SA. Etanercept for refractory asthma therapy. Expert Opin Investig Drugs 2006;15:1279-1281
85. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomised phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:1463-1472
86. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int 2006;26:1029-1039